Boston Scientific posted $5.442 billion in second-quarter 2026 revenue, beating market expectations, according to an SEC Form 8-K filing.
📊 Price at Time of Writing (July 29, 2026, 21:07 KST)
$46.06 ▲ +1.21%
≈ ₩66,695 (rate: 1,448)
Q2 Earnings at a Glance
Boston Scientific's second-quarter revenue rose 7.5% year-over-year, landing at the high end of the company's guided range of 5.5% to 7.5%. Net income also increased to $907 million, up from $797 million a year earlier. During the quarter, the company completed a $2 billion share buyback program and invested $1.5 billion in cardiac device maker MiRus, acquiring roughly a 34% stake.
- Revenue: $5.442 billion, up 7.5% year-over-year
- Adjusted EPS: $0.86, above the high end of the company's own guidance of $0.82–$0.84
- Net income: $907 million, up from $797 million a year earlier
Next-Quarter Outlook
The company expects third-quarter 2026 revenue to grow 3% to 5% year-over-year on a reported basis. For the full year, it projects reported revenue growth of 5.5% to 6.5% and adjusted EPS of $3.28 to $3.32. CEO Mike Mahoney said, "Our team delivered solid results this quarter despite a dynamic environment," adding that the company remains "confident in our long-term growth as we focus investment on our highest-performing businesses."
Market Reaction
As of 9:07 p.m. KST on July 29, 2026, Boston Scientific shares traded at $46.06, up 1.21% from the previous close. Investing.com reported that the results beat market expectations, with EPS coming in $0.03 above estimates and revenue also topping forecasts. However, the Wall Street Journal reported that the company lowered its earnings outlook ahead of a restructuring. MassDevice likewise noted that despite beating second-quarter estimates, the company once again trimmed its full-year 2026 guidance.
Segment Breakdown
- Cardiovascular segment: $3.624 billion, up 8.3% year-over-year
- MedSurg segment (Endoscopy, Urology, Neuromodulation): $1.818 billion, up 5.9% year-over-year
- — Endoscopy: $793 million, up 7.6%
- — Urology: $684 million, up 1.1%
- — Neuromodulation: $341 million, up 12.7%
This article was automatically generated based on the original SEC Form 8-K filing and news reports, with the goal of quickly conveying key data immediately after the announcement. Readers are advised to review the company's official filing before making trading decisions. The stock price reflects the time of writing and may differ from the current price.
